Below is the Quote on Astrazeneca Pharma Ltd By Mr. Yash Gupta - Equity Research Associate, Angel Broking Ltd
"Astrazeneca Pharma India Limited has received permission for import and market for cancer drug i.e Acalabrutinib 100mg capsules (Calquence ®) from the Drugs Controller General of India in Form CT-20 (Marketing Authorization- Additional Indication). AstraZeneca Pharma India Limited will launch Calquence® in India on October 21, 2020. Acalabrutinib 100mg capsules Indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy or indicated for treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL). This is positive development for Astrazeneca Pharma India Limited."
Above views are of the author and not of the website kindly read disclaimer